Abstract

Heme serves as a prosthetic group in hemoproteins, including subunits of the mammalian mitochondrial electron transfer chain. The first enzyme in vertebrate heme biosynthesis, 5-aminolevulinic acid synthase 1 (ALAS1), is ubiquitously expressed and essential for producing 5-aminolevulinic acid (ALA). We previously showed that Alas1 heterozygous mice at 20–35 weeks (aged-A1+/−s) manifested impaired glucose metabolism, mitochondrial malformation in skeletal muscle, and reduced exercise tolerance, potentially linked to autophagy dysfunction. In this study, we investigated autophagy in A1+/−s and a sarcopenic phenotype in A1+/−s at 75–95 weeks (senile-A1+/−s). Senile-A1+/−s exhibited significantly reduced body and gastrocnemius muscle weight, and muscle strength, indicating an accelerated sarcopenic phenotype. Decreases in total LC3 and LC3-II protein and Map1lc3a mRNA levels were observed in aged-A1+/−s under fasting conditions and in Alas1 knockdown myocyte-differentiated C2C12 cells (A1KD-C2C12s) cultured in high- or low-glucose medium. ALA treatment largely reversed these declines. Reduced AMP-activated protein kinase (AMPK) signaling was associated with decreased autophagy in aged-A1+/−s and A1KD-C2C12s. AMPK modulation using AICAR (activator) and dorsomorphin (inhibitor) affected LC3 protein levels in an AMPK-dependent manner. Our findings suggest that heme deficiency contributes to accelerated sarcopenia-like defects and reduced autophagy in skeletal muscle, primarily due to decreased AMPK signaling.

Details

Title
Heme deficiency in skeletal muscle exacerbates sarcopenia and impairs autophagy by reducing AMPK signaling
Author
Akabane, Takeru 1 ; Sagae, Hiromori 1 ; van Wijk, Koen 2 ; Saitoh, Shinichi 2 ; Kimura, Tomohiro 2 ; Okano, Satoshi 2 ; Kodama, Ken 3 ; Takahashi, Kiwamu 4 ; Nakajima, Motowo 4 ; Tanaka, Tohru 5 ; Takagi, Michiaki 6 ; Nakajima, Osamu 2 

 Yamagata University Faculty of Medicine, Department of Functional Genomics, Major of Innovative Medical Science Research, Yamagata University School of Medicine/Research Center for Molecular Genetics, Institute for Promotion of Medical Science Research, Yamagata, Japan (GRID:grid.268394.2) (ISNI:0000 0001 0674 7277); Yamagata University Faculty of Medicine, Department of Orthopaedic Surgery, Yamagata, Japan (GRID:grid.268394.2) (ISNI:0000 0001 0674 7277) 
 Yamagata University Faculty of Medicine, Department of Functional Genomics, Major of Innovative Medical Science Research, Yamagata University School of Medicine/Research Center for Molecular Genetics, Institute for Promotion of Medical Science Research, Yamagata, Japan (GRID:grid.268394.2) (ISNI:0000 0001 0674 7277) 
 KIYAN PHARMA Co., Ltd., Tokyo, Japan (GRID:grid.268394.2) 
 SBI Pharmaceuticals Co., Ltd., Tokyo, Japan (GRID:grid.476775.0) 
 KIYAN PHARMA Co., Ltd., Tokyo, Japan (GRID:grid.476775.0) 
 Yamagata University Faculty of Medicine, Department of Orthopaedic Surgery, Yamagata, Japan (GRID:grid.268394.2) (ISNI:0000 0001 0674 7277) 
Pages
22147
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3110577754
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.